The Food and Drug Administration has raised questions about three out of four studies that General Mills used to support health claims for the nation's top-selling breakfast cereal, Cheerios.
The oat cereal is one of the biggest earners at General Mills, which argued this summer that it should be allowed to say that a diet of Cheerios cuts levels of low-density lipoprotein (sometimes referred to as "bad") cholesterol by specific amounts.
The FDA's letter, sent Oct. 9 and made public after a Freedom of Information Act request by the Star Tribune, said studies submitted to the FDA for two claims -- which appeared on boxes as "4% in 6 weeks" and "10% in one month"-- were either too short or incomplete.
General Mills dropped both claims from its boxes of Cheerios, according to a spokesman, but it continues to press the matter with the FDA.
Cereal king
The back-and-forth involves the sometimes-arcane rules of food labeling, which nevertheless can affect millions of dollars in sales.
Cheerios has long been the breakfast cereal king -- about 1 out of every 8 boxes of cereal sold at supermarkets, according to data from the Nielsen company. It claims more than twice the market share of the runner-up, Kellogg's Special K.
But Cheerios has been under regulatory fire ever since the FDA said this summer that labeling on its boxes overstepped the rules for health claims.